Why This Little Known Biotech Is Pharma's New Poster Child for Price Gouging Post author:Sam Post published:December 19, 2017 Post category:BioPharma Another lawmaker is taking on a pharmaceutical company for drug pricing. Source: BioSpace You Might Also Like Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal January 3, 2018 Frazier-Backed Mavupharma Scores $20M to Fund STING Program November 28, 2017 Blue Earth Diagnostics Receives Positive Opinion For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer March 23, 2017
Blue Earth Diagnostics Receives Positive Opinion For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer March 23, 2017